The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies.
Wolfgang Emanuel Zürrer, Lionel Wettstein, Helena Aicher, Milan Scheidegger, Benjamin Victor Ineichen
Translational Psychiatry October 10, 2025 DOI: 10.1038/s41398-025-03638-3 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review and meta-analysis Qualitative Peer reviewed |
|---|---|
| Population | Animal models of neurological and psychiatric disorders |
| Intervention | Salvinorin A |
| Dose | 0.1-10 mg/kg |
| Topics | Salvia divinorum |
| Citations | 3 |
| Key findings | Salvinorin A exhibits anti-nociceptive, anti-inflammatory, neuroprotective, and anti-addictive effects in animal models, but also anxiogenic effects and motor and cognitive impairment. |
Abstract
Salvinorin A, the main psychoactive compound of Salvia divinorum, is a potent and selective kappa opioid receptor agonist. While human clinical trials remain limited, animal studies suggest potential therapeutic applications in neurological and psychiatric disorders. This systematic review and meta-analysis aims to synthesize these preclinical findings, addressing three questions: (1) What is the therapeutic potential of salvinorin A in animal models of neurological and psychiatric disorders? (2) What are its toxic effects on behaviour, cognition, and physiological function? (3) What are its pharmacokinetic characteristics? A systematic search of Medline, Web of Science, and EMBASE for studies published up to June 28, 2024, identified 1718 publications, of which 82 were included in the qualitative synthesis and 10 in the meta-analysis. Salvinorin A has been tested in animal models of pain, cerebrovascular insults, addiction, and depression. It exhibited anti-nociceptive, anti-inflammatory, neuroprotective, and anti-addictive effects. Findings on depression were inconsistent, with both antidepressant and depressogenic outcomes reported. Toxicity data indicate anxiogenic effects and motor and cognitive impairment, with minimal impact on vital parameters. Applied doses ranged from 0.1-10 mg/kg, with lower doses in stroke models. Pharmacokinetic data show rapid onset, fast peak, and a half-life of approximately one hour. Sixteen structurally distinct salvinorin A analogues were identified with potentially improved safety and pharmacokinetic profiles. Our findings support the therapeutic potential of salvinorin A for pain, addiction, and stroke, though its side effect profile may limit clinical application. The development of novel analogues could address these challenges.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Salvinorin A showed anti-nociceptive, anti-inflammatory, neuroprotective, and anti-addictive effects in animal models, but also anxiogenic effects and motor and cognitive impairment, with inconsistent findings on depression.
Synthesized
Comparable studies
Other systematic reviews and meta-analyses on salvia divinorum, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Salvinorin A in humans: A systematic review of pharmacokinetics, pharmacodynamics, and safety Participants in 12 clinical trials of salvinorin A, mostly medically healthy,... | 2026 | Systematic review | n = 174 |
| The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies Animal models of neurological and psychiatric disorders | 2025 | Systematic review and meta-analysis |
Citations in the library
Cites 70
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
and 65 more in the library